Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (391-400 of 539) with videos related to

Pageof 54
Sort By:
British Journal of Haematology|January 28, 2009
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guidelinePaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
Haematologica|August 20, 2016
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.
Cancer Immunology Research|July 16, 2020
CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti-PD-L1 TreatmentValentina Volpin, Tillmann Michels, Antonio Sorrentino, et al.
Blood|January 6, 2023
A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myelomaNicola Giesen, Manik Chatterjee, Christof Scheid, et al.
Leukemia|November 4, 2021
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trialLisa B Leypoldt, Britta Besemer, Anne Marie Asemissen, et al.
Haematologica|April 5, 2015
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.
European Journal of Haematology|April 4, 2017
Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsEMarc-Andrea Baertsch, Jana Schlenzka, Katharina Lisenko, et al.
Leukemia|May 25, 2021
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III TrialHans Salwender, Ahmet Elmaagacli, Maximilian Merz, et al.
British Journal of Haematology|May 17, 2012
Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortiumDaniele Campa, Alessandro Martino, Juan Sainz, et al.
Hematology (Amsterdam, Netherlands)|February 26, 2024
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trialHans Salwender, Niels Weinhold, Axel Benner, et al.
Pageof 54

Showing results (391-400 of 539) with videos related to

Sort By:
Pageof 54
British Journal of Haematology|January 28, 2009
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guidelinePaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
Haematologica|August 20, 2016
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.
Cancer Immunology Research|July 16, 2020
CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti-PD-L1 TreatmentValentina Volpin, Tillmann Michels, Antonio Sorrentino, et al.
Blood|January 6, 2023
A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myelomaNicola Giesen, Manik Chatterjee, Christof Scheid, et al.
Leukemia|November 4, 2021
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trialLisa B Leypoldt, Britta Besemer, Anne Marie Asemissen, et al.
Haematologica|April 5, 2015
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.
European Journal of Haematology|April 4, 2017
Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsEMarc-Andrea Baertsch, Jana Schlenzka, Katharina Lisenko, et al.
Leukemia|May 25, 2021
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III TrialHans Salwender, Ahmet Elmaagacli, Maximilian Merz, et al.
British Journal of Haematology|May 17, 2012
Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortiumDaniele Campa, Alessandro Martino, Juan Sainz, et al.
Hematology (Amsterdam, Netherlands)|February 26, 2024
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trialHans Salwender, Niels Weinhold, Axel Benner, et al.
Pageof 54